We’ve put some small files called cookies on your device to make our site work.
We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.
Change my preferences
I'm OK with analytics cookies
As part of the 2019-20 Community Pharmacy Quality Scheme, contractors were asked to complete a valproate audit, following Baroness Cumberlege’s report: First Do No Harm and the Medicines and Healthcare Regulatory Agency safety requirements for use of valproate in women and girls of childbearing age and trans men who are biologically able to be pregnant.
This report details the results and findings and makes recommendations on further actions to reduce preventable harm.
Published 11 August 2022.